Literature DB >> 19574784

Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by positron emission tomography and treated with curative intent.

Kailash Narayan1, Richard J Fisher, David Bernshaw, Ramdave Shakher, Rodney J Hicks.   

Abstract

PURPOSE: The aim of this retrospective analysis was to assess whether parameters derived from magnetic resonance imaging (MRI) and positron emission tomography (PET) provide incremental prognostic value compared with International Federation of Gynecology and Obstetrics (FIGO) stage in cervix cancer patients treated with curative intent using concurrent chemoradiotherapy.
MATERIALS AND METHODS: This was a retrospective study of patients with locoregionally advanced cervical cancer staged by examination under anesthesia and pretreatment MRI and PET. Potential prognostic factors examined were derived from either clinical evaluation (age, FIGO stage, clinical diameter, histology), MRI (corpus invasion, tumor volume), or PET (lymph node metastasis). Outcome measures examined were overall survival, relapse-free survival, time to failure, local failure, nodal failure, and distant failure.
RESULTS: There were 206 eligible patients. The mean potential follow-up was 4.4 years. At 5 years, for all patients, overall survival rate was 59%. For all outcome measures apart from local failure, for which adenocarcinoma histology was the most powerful adverse prognostic factor (HR, 4.29; P < 0.0001), lymph node status on PET was the dominant unifactor and multifactor prognostic factor. Corpus involvement on MRI was significantly associated with nodal involvement on PET but of MRI-derived parameters only tumor volume has prognostic value, limited to time to failure and nodal failure.
CONCLUSIONS: Nodal status on PET was the major predictor of outcome in locally advanced cervix cancer treated with chemoradiation and was superior to FIGO staging. Tumor volume measured from MRI appears to be an important predictor of loco-regional relapse.

Entities:  

Mesh:

Year:  2009        PMID: 19574784     DOI: 10.1111/IGC.0b013e3181a58d3f

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  25 in total

Review 1.  [The 2019 FIGO classification for cervical carcinoma-what's new?]

Authors:  L-C Horn; C E Brambs; S Opitz; U A Ulrich; A K Höhn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

2.  Treatment outcomes of patients with cervical cancer with complete metabolic responses after definitive chemoradiotherapy.

Authors:  Cem Onal; Mehmet Reyhan; Ozan C Guler; Ali Fuat Yapar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

Review 3.  Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours.

Authors:  Giovanni Lucignani; Steven M Larson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05       Impact factor: 9.236

4.  Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.

Authors:  Helen J Mackay; Lari Wenzel; Linda Mileshkin
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

5.  FDG-PET-based prognostic nomograms for locally advanced cervical cancer.

Authors:  Elizabeth A Kidd; Issam El Naqa; Barry A Siegel; Farrokh Dehdashti; Perry W Grigsby
Journal:  Gynecol Oncol       Date:  2012-06-24       Impact factor: 5.482

6.  A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer.

Authors:  Antoine Schernberg; Sylvain Reuze; Fanny Orlhac; Irène Buvat; Laurent Dercle; Roger Sun; Elaine Limkin; Alexandre Escande; Christine Haie-Meder; Eric Deutsch; Cyrus Chargari; Charlotte Robert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-09-15       Impact factor: 9.236

7.  Significance of uterine corpus tumor invasion in early-stage cervical cancer.

Authors:  K Matsuo; H Machida; E A Blake; T Takiuchi; M Mikami; L D Roman
Journal:  Eur J Surg Oncol       Date:  2017-02-03       Impact factor: 4.424

8.  Complementary Prognostic Value of Pelvic Magnetic Resonance Imaging and Whole-Body Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in the Pretreatment Assessment of Patients With Cervical Cancer.

Authors:  Evis Sala; Maura Micco; Irene A Burger; Derya Yakar; Marisa A Kollmeier; Debra A Goldman; Mithat Gonen; Kay J Park; Nadeem R Abu-Rustum; Hedvig Hricak; Hebert Alberto Vargas
Journal:  Int J Gynecol Cancer       Date:  2015-10       Impact factor: 3.437

9.  Positron-emission tomography for locally advanced cervical cancer: a survey assessing Canadian practice patterns and access.

Authors:  R Banerjee; G Dundas; C Doll
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

10.  Tumor growth patterns on magnetic resonance imaging and treatment outcomes in patients with locally advanced cervical cancer treated with definitive radiotherapy.

Authors:  Shintaro Tsuruoka; Masaaki Kataoka; Yasushi Hamamoto; Akifumi Tokumasu; Kotaro Uwatsu; Hiromitsu Kanzaki; Noriko Takata; Hirofumi Ishikawa; Ayaka Ouchi; Teruhito Mochizuki
Journal:  Int J Clin Oncol       Date:  2019-05-11       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.